

7 April 2026

**Cambridge Cognition Holdings plc**  
("Cambridge Cognition", the "Company" or the "Group")

**Appointment of Nominated Adviser and Joint Broker**

Cambridge Cognition Holdings plc (AIM: COG), the neuroscience technology company whose digital cognitive assessments drive scientific discovery, accelerate drug development and improve patient care, announces the appointment of Cavendish Capital Markets Limited as the Company's Nominated Adviser and Joint Broker with immediate effect.

Singer Capital Markets remain in their role as Joint Corporate Broker.

**Enquiries:**

**Cambridge Cognition Holdings plc**

Rob Baker, Chief Executive Officer

Ronald Openshaw, Chief Financial Officer

Tel: 01223 810700

[press@camcog.com](mailto:press@camcog.com)

**Cavendish Capital Markets Limited (NOMAD and Joint Broker)**

Geoff Nash / Elysia Bough / Joe Smith

Harriet Ward

Nigel Birks

Tel: 020 7220 0500

Corporate Finance

Corporate Broking

LS Specialist Sales

**Singer Capital Markets Limited (Joint Broker)**

Amber Higgs / James Serjeant / Daniel Ingram

Tel: 020 7496 3000

**Notes to Editors**

**About Cambridge Cognition**

Cambridge Cognition is a neuroscience technology company whose digital cognitive assessments drive scientific discovery, accelerate drug development and improve patient care.

Built on rich, curated data and deep technical expertise we are building a strong global brand with scalable technology that will support the rising world demand for diagnosing and treating brain health. The Company creates shareholder value through organic sales growth, strategic partnerships, joint ventures, and spinouts. The Company has identified four market sectors:

- **Clinical Studies** for new pharmaceuticals;
- **Academic Research** for scientists to understand CNS disorders;
- **Healthcare** to provide physicians with cognitive assessments to allow them to diagnose and treat patients; and,
- **Consumer Health & Wellness** to provide individuals access to accurate, reliable, and meaningful data to assess their cognitive health.

For further information, visit: [www.cambridgecognition.com](http://www.cambridgecognition.com)

### **Existing Board - AIM Rule 17 Disclosure**

The Company confirms the following director disclosures pursuant to AIM Rule 17 and Schedule Two paragraph (g) of the AIM Rules for Companies.

*Steven Powell (Chairman)*

Ribonexus SAS, a company which Steven Powell is a director of, entered into a court-ordered liquidation in April 2024. The Company is currently still in liquidation.

Steven was previously a director of LCC Therapeutics, resigning on 17 June 2025. After he had left employment, the company appointed an administrator and later entered into a creditors voluntary liquidation on 16 October 2025. The Company is currently still in liquidation.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [ms@seg.com](mailto:ms@seg.com) or visit [www.ms.com](http://www.ms.com).

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

APPUPUMPCUPQGMP